Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Coherus Oncology (CHRS) Inventory Average: 2019-2025

Historic Inventory Average for Coherus Oncology (CHRS) over the last 7 years, with Sep 2025 value amounting to $3.3 million.

  • Coherus Oncology's Inventory Average fell 94.02% to $3.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.3 million, marking a year-over-year decrease of 94.02%. This contributed to the annual value of $33.4 million for FY2024, which is 34.11% down from last year.
  • Coherus Oncology's Inventory Average amounted to $3.3 million in Q3 2025, which was down 18.30% from $4.0 million recorded in Q2 2025.
  • In the past 5 years, Coherus Oncology's Inventory Average ranged from a high of $65.4 million in Q3 2023 and a low of $3.3 million during Q3 2025.
  • In the last 3 years, Coherus Oncology's Inventory Average had a median value of $54.9 million in 2024 and averaged $40.7 million.
  • Its Inventory Average has fluctuated over the past 5 years, first surged by 265.23% in 2021, then tumbled by 94.02% in 2025.
  • Over the past 5 years, Coherus Oncology's Inventory Average (Quarterly) stood at $37.6 million in 2021, then fell by 11.59% to $33.3 million in 2022, then soared by 94.54% to $64.7 million in 2023, then plummeted by 59.93% to $25.9 million in 2024, then tumbled by 94.02% to $3.3 million in 2025.
  • Its Inventory Average was $3.3 million in Q3 2025, compared to $4.0 million in Q2 2025 and $3.9 million in Q1 2025.